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Abstract
Background: Innovations in technology have contributed to rapid changes in the way that modern biomedical
research is carried out. Researchers are increasingly required to endorse adaptive and flexible approaches to
accommodate these innovations and comply with ethical, legal and regulatory requirements. This paper explores
how Dynamic Consent may provide solutions to address challenges encountered when researchers invite
individuals to participate in research and follow them up over time in a continuously changing environment.
Methods: An interdisciplinary workshop jointly organised by the University of Oxford and the COST Action CHIP
ME gathered clinicians, researchers, ethicists, lawyers, research participants and patient representatives to discuss
experiences of using Dynamic Consent, and how such use may facilitate the conduct of specific research tasks. The
data collected during the workshop were analysed using a content analysis approach.
Results: Dynamic Consent can provide practical, sustainable and future-proof solutions to challenges related to
participant recruitment, the attainment of informed consent, participant retention and consent management, and
may bring economic efficiencies.
Conclusions: Dynamic Consent offers opportunities for ongoing communication between researchers and research
participants that can positively impact research. Dynamic Consent supports inter-sector, cross-border approaches
and large scale data-sharing. Whilst it is relatively easy to set up and maintain, its implementation will require that
researchers re-consider their relationship with research participants and adopt new procedures.
Keywords: Dynamic consent, Participant engagement, Research communication, Ethics, Biobank, Clinical trials,
Clinical research, Software tools
Background
Conducting biomedical research is essential to increase
our understanding of biological and molecular mecha-
nisms underlying disease, test the efficiency of new
drugs, interventions and devices, and move toward per-
sonalised medicine [1]. Biomedical research requires the
continuous collection of biological samples, health and
outcome data from representative samples of patients
and populations and the follow up of these groups over
time [2]. As innovations in technology develop at expo-
nential speed, researchers need to have flexibility in the
conduct of their research to be able to react quickly to
ongoing developments and accelerate medical discovery
and the development of new treatment strategies. How-
ever, traditional approaches to the planning and conduct
of biomedical research projects present a number of
challenges.
First, recruiting enough participants, or reaching out
to the population of interest, is often difficult [3, 4]. This
is particularly true in genetic research which experiences
lower recruitment rates than other types of biomedical
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research [5]. Participant recruitment may be hindered by
a lack of manpower or funding to organise large
information-giving and enrolment campaigns. It may
also be inhibited by clinical staff ’s limited familiarity or
understanding of research objectives and fears that it
will interrupt patient care [6]. Furthermore, patients may
not understand the objectives of the research, may not
be willing or able to travel to the research centre [7], or
may not speak the language used by researchers [8].
Second, obtaining informed consent from research
participants can be demanding. The objective of the in-
formed consent process is to ensure that research partic-
ipants understand the aims and risks of the research and
participate in the research voluntarily with this know-
ledge. However, research participants often do not
understand the content of the information sheet or the
consent form for the study, particularly if the consent
form is lengthy and includes complex terminology [9, 10].
While some participants may be satisfied with receiving
information about the research project only once during
the recruitment phase, others may want to go through the
information several times and may have additional ques-
tions or concerns. Assessing the participants’ health liter-
acy and understanding of the research objectives and
implications can be difficult and time-consuming [11]. If
new research needs arise that were not foreseen and in-
cluded in the original consent document, collecting new
consent from research participants may be expensive and
burdensome, particularly if additional consent requires
face-to-face interaction or the mailing of paper consent
forms. If multiple consents are collected over time, keep-
ing records of these consents can be complicated, particu-
larly in cohort studies, or in projects spanning several
years and multiple iterations where paper consent forms
are stored in several institutions [11].
Third, retaining research participants in projects is
often challenging [8, 12]. Participants may drop out be-
cause they experience changes in their condition, re-
spond adversely to the intervention under investigation,
move away from the study area or lose interest in the
study. Participant drop-out jeopardises the quality of the
data, the significance of research findings, and the con-
duct of follow-up studies [13]. In addition, clinical re-
searchers often need to collect patient-reported outcome
data over time to better understand disease symptoms
and the impact on disease burden [14]. Researchers con-
ducting population-based health surveys may want to
send new health questionnaires to their participants.
Regularly collecting additional data from participants
may be administratively demanding and costly, particu-
larly if paper forms have to be sent in the mail.
A number of innovative strategies have been devel-
oped which aim to offer practical solutions and tools to
facilitate the processes described above. For instance,
clinical research projects have developed in-home clin-
ical trial support programs to enable patients who can-
not travel long distance to clinical sites to participate in
research [12]. Projects are coordinating efforts between
research teams and infrastructure support at clinical
sites to improve recruitment rates [15]. The use of new
technologies such as mobile phones and applications is
also explored to facilitate ongoing data collection [16].
In addition, large efforts have been made to investigate
designs for informed consent that both facilitate the
conduct of biomedical research and protect the interests
of research participants. A strategy that has received
considerable attention is the use of broad consent. Broad
consent is an alternative to the more customary specific
consent; many consider specific consent too difficult to
apply in biobank research where biological sample col-
lections are built as research resources for multiple uses
[17]. Definitions of broad consent vary and span from
“consent to a wide (broadly specified) range of options”
[18] to consent to “an unspecified range of future re-
search subject to a few content and/or process restric-
tions” [19]. In general, broad consent can be described
as a tool that enables research participants to consent to
a variety of research projects. Blanket consent, that is
consent to an unlimited range of options, has also been
suggested as a potential strategy to facilitate the conduct
of research [18]. More recently, meta-consent, an ap-
proach which enables individuals to express preferences
regarding which type of consent they want to give for
which type of research (for example, blanket consent to
research on biological samples, specific consent to re-
search led by industrial actors) has been described as a
solution that may positively affect people’s willingness to
participate in research [20].
In principle, broad and blanket consent may facilitate
the conduct of research as researchers do not have to
consent research participants each time new research
questions or situations arise. However, there is some
controversy regarding the extent to which these ap-
proaches to consent enable research participants to be
truly informed about the objectives and details of the re-
search and are respectful of the participants’ values and
personal preferences [18, 21]. Furthermore, it remains
unclear whether broad consent may help address some
of the challenges described earlier. For instance, it is un-
likely that the use of broad consent facilitates reaching
out to populations that would not normally participate
in research because they do not have easy access to re-
search facilities or do not understand why they should
participate. In addition, the use of broad consent may
not provide any protection against unforeseen events
such as regulatory changes. The difficulties that the
Swedish population biobank Lifegene encountered are il-
lustrative of this issue. Although the biobank had already
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recruited many participants and collected their broad
consent, in 2013, the Swedish Data Inspection Board de-
cided to temporarily suspend the biobank’s activities as
it considered that broad consent did not describe the
biobank research in a way that would satisfy the require-
ments of forthcoming regulation [22, 23]. Similarly, it is
unclear whether meta-consent may positively impact
participant retention or facilitate ongoing health data
collection in research projects.
Another strategy to facilitate the conduct of biomed-
ical research while protecting the interests of research
participants is Dynamic Consent. Dynamic Consent is a
term used to describe personalised, online consent and
communication platforms [3]. Such platforms are pri-
marily designed to achieve two objectives: 1) facilitate
the consent process and 2) facilitate two-way, ongoing
communication between researchers and research par-
ticipants. It should be noted that Dynamic Consent is
not the same as specific consent. Rather, it can be setup
to accommodate different types of consent depending
on the research objectives and context [24]. For instance,
biobank research participants may give their broad con-
sent to research through a Dynamic Consent platform.
Later in time they may use the platform to give their
new consent to new research activities that were not
foreseen in the original consent (e.g. feedback of genetic
research results), or they may alter their consent choices
in response to their changing circumstances [3]. Al-
though a central objective of Dynamic Consent is to
offer some flexibility to the consent process, Dynamic
Consent platforms may also be used for communication
in both clinical and population-based research projects.
For instance, researchers may use the platform to give
participants regular updates about the research, or ask
participants to upload new health data throughout the
duration of the research project. Research participants
may use the platform to set up their preferences regarding
access to their health data by third parties or how often
they would like to be contacted by the researchers. In re-
cent years, several clinical and population-based research
projects have tested online Dynamic Consent platforms
[25–31], initiatives welcomed by research participants
[29, 32]. Also in health care settings, projects are ex-
ploring the use of online platforms for patient consent to
the re-use of electronic patient records for research [33].
In the literature, there is emphasis on discussing how
Dynamic Consent may enhance the research partici-
pants’ right to make autonomous choices regarding their
participation in research, improve their comprehension
of the consent process and promote their engagement in
the research endeavour [11, 24, 34–37]. Less attention
has been given to exploring specific ways that Dynamic
Consent may facilitate the conduct of medical research.
The key purpose of this paper is to explore how
Dynamic Consent can help researchers address the
challenges encountered (in population-based and clin-
ical research) when inviting individuals to participate
in research and following them up over time in a
continuously changing environment.
Methods
In October 2015, the Centre for Health, Law and Emerging
Technologies (HeLEX) [22] at the University of Oxford and
Working Group 1 of the COST Action CHIP ME IS1303
“Citizen's Health through public-private Initiatives: Public
health, Market and Ethical perspectives” [23] (a European
Union Framework which brings together European experts)
conducted an interdisciplinary two-day workshop at the
University of Oxford to share experiences of implementing
Dynamic Consent within research projects. Representatives
from a range of disciplines contributed to the workshop in-
cluding ethicists, lawyers, clinicians, researchers, research
nurses and research participants. First, the workshop mem-
bers discussed Dynamic Consent approaches that are im-
plemented in clinical and biobank research projects and
identified key elements in these projects that characterise
Dynamic Consent. Several workshop members reported
how Dynamic Consent had been designed and applied in
their projects. Second, the workshop members mapped a
process flowchart describing the main tasks that re-
searchers have to complete in order to include and follow
up individuals in research projects. For each task, the work-
shop members identified challenges encountered that may
delay or render task completion difficult. Then a discussion
followed as to how Dynamic Consent may facilitate the
conduct of each task, particularly in terms of increased re-
quirements for transparency, information-sharing and par-
ticipant engagement. The workshop members were made
aware that the findings from the workshop would be pub-
lished and were offered the opportunity to contribute to
the writing of this paper. Notes were taken during the
workshop; the workshop organisers summarised and ana-
lysed the data using a content analysis approach with an in-
ductive approach [38]. First, the notes were sorted and the
data categorised according to the main tasks that had been
listed in the process flowchart. Then the data were con-
densed to reflect the main points made by the workshop
members. A preliminary paper summarising the workshop
findings was shared with workshop members for validation.
Their comments and corrections were integrated into the
results. This research did not require informed consent or
approval from an ethics board.
Results
Discussions at the workshop demonstrated that Dy-
namic Consent can provide practical solutions to the
conduct of four main tasks: participant recruitment, col-
lection of informed consent, participant retention and
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consent management as summarised below and de-
scribed in Fig. 1. For each task, we provide concrete ex-
amples from research projects to describe how Dynamic
Consent can address these challenges.
Participant recruitment
A Dynamic Consent platform can be set up to provide
most of the information about a research project online
in a user-friendly and standardised way across research
sites (including video, podcast, web, or mobile applica-
tions). The information can be given in as many lan-
guages as necessary by use of subtitles, dubbed
soundtracks and translated text, and at a level of detail
that satisfies the specific needs of participants [16, 18].
In principle, the information is accessible to large groups
regardless of their geographical location since it is on
the Internet, thus potentially broadening the research
population. This may be particularly useful in rare dis-
ease research where the number of cases is often low
and patients are geographically scattered. An example of
this is the website for RUDY, a study in rare diseases of
the bones, joints and blood vessels headed by a research
team at the University of Oxford [39]. The website pro-
vides simple information about the research and explains
how patients diagnosed with a relevant rare disease, or
their relatives, may register to become a research partici-
pant in the study. Individuals who would like to register
are invited to use the online secure registration system
and are informed that they will be contacted after regis-
tration for completion of the consent process, usually by
telephone, by a research team member [27]. Patients can
consult information sheets and consent forms on the
website. Since most of the information about the project
is available online, the time needed for individual discus-
sions with potential research participants is reduced.
To reach out to populations who are not entirely fa-
miliar with the use of online technologies or do not have
access to them, the use of a Dynamic Consent platform
may be accompanied with conventional methods such as
paper leaflets or local information-giving meetings. This
strategy was used in the Cooperative Health Research In
South Tyrol (CHRIS) study [40], a population-based
study aiming to investigate the genetic and molecular
basis of age-related common chronic conditions and
their interaction with life-style and environment in the
general population [28]. To recruit participants from
rural areas to the study, village information meetings,
broadcasts of information to the public through the local
media and web-based recruitment were combined to
maximise family participation. However, it is anticipated
that the use of multiple methods may become less import-
ant as people’s access and familiarity with the Internet im-
proves and they become acquainted with Dynamic
Consent platforms. Once participants are recruited, the
platform may also be used to regularly update them about
recruitment progress and how they can improve aware-
ness of the research within their communities.
Collection of informed consent
Although standard ethical practice is to have face-to-
face dialogue with potential research participants at least
for the attainment of the original consent, Dynamic
Consent may challenge such practice. In the RUDY
study, potential participants discuss the study with the
research team in telephone consultations. Then, the par-
ticipants may choose to download the informed consent
form from the website, sign it and send it to the research
team by postal mail or email, or they may give their elec-
tronic sign-off [27]. Research projects may use mecha-
nisms to assess the participants’ level of comprehension
of the research online, for instance by asking research
participants to correctly answer interactive questions
before providing their consent [33]. As an illustration,
potential participants in the Harvard Personal Genome
Fig. 1 Dynamic Consent’s contribution to phases of research
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Project (PGP) [41], a project aiming to publicly share the
genome, health and trait data of thousands of volun-
teers, are required to complete an online enrolment
examination to demonstrate their comprehension of the
risks and protocols associated with being a member of
the project before they can give their informed consent
to participate in the research [42]. Individuals who fail
the examination or do not complete it are not eligible to
participate in the research.
A Dynamic Consent platform enables researchers to
refine consent in a more nuanced way that the trad-
itional ‘all or nothing’ approach (either participate in the
research or not) [43]. For instance, researchers may give
participants the choice to consent to some or all aspects
of the research depending on their personal preferences
and beliefs. Researchers may also ask research partici-
pants which types of data access by third parties are
acceptable to them. For example, in the Platform for
Engaging Everyone Responsibly (PEER) [44], a tool de-
veloped by the Genetic Alliance [45] and Private Access
[46], research participants may indicate the type of ac-
cess that they approve and do not approve of, in a
matrix. Researchers may also ask participants to consent
to a range of other activities at any time; these include
data deposit in public research databases [47], data shar-
ing with drug companies and privately-funded institu-
tions [48, 49], or the use of biological samples in case of
death or incapacity. This solution enables researchers to
know exactly which levels of privacy risks research par-
ticipants are willing to take and which data may or may
not be used in the research. Access preferences can be
updated at any time depending on the specific needs
and preferences of each research participant and may be
directly connected to the databases [50]. Rather than
creating potential restrictions on data sharing, such a
strategy may enhance data sharing. This is because re-
search participants often consider that the altruistic ben-
efits of sharing their data for research outweigh potential
risks [33, 51, 52] but anticipate being consulted about
how their data are used and expect transparency regard-
ing such decisions [51, 53].
A Dynamic Consent platform may also enable partici-
pants to consent online to the feedback of genetic re-
search results, even years after a project starts. For
instance, participants in the CHRIS study may indicate
in their personal settings whether they would like to be
contacted if results are produced in the research which
may offer “chances of therapy or prevention”, and by
whom (for example the hospital which recruited them in
the research or their general practitioner) [50]. Enabling
participants to consent to the feedback of their genetic
research results may be useful in research projects plan-
ning to recruit participants in future follow-up studies
on the basis of their genotype [54]. In principle, the
results could be fed back through the platform if the ne-
cessary requirements in terms of genetic counselling are
met. As an illustration, private actors such as the direct-
to-consumer genetic testing company 23andMe combine
user-friendly online feedback services with genetic coun-
selling by telephone to those customers who want it [55].
Participant retention
Dynamic Consent enables researchers to provide partici-
pants with regular updates about early findings, follow-up
studies, key outcomes, presentations and publications, or
invite them to information meetings or follow-up consulta-
tions. A recent survey conducted among participants in the
CHRIS study shows that ongoing communication moti-
vates research participants to continue with the research
[50], an observation also made in previous studies [29, 32].
Importantly, researchers may use a Dynamic Consent plat-
form to ask participants to upload additional health data
online. This may become a critical feature of Dynamic
Consent as researchers are increasingly moving away
from traditional, large-scale randomised controlled tri-
als under which measurements from thousands of
people are harvested, to trials conducted on smaller
patient groups that are stratified based on presence
or absence of specific biomarkers [56]. In these trials,
relying solely on statistical methods or average re-
sponses to assess new treatment strategies is hardly
optimal since the numbers are too small to quantify
positive and negative uncertainties such as benefit
and risk [57]. Researchers need to rely more on pa-
tients’ experiences by regularly collecting data from
them regarding health outcomes, quality of life, side
effects and personal utility of interventions over time
[43]. In the RUDY study, participants use the online
platform to fill in health questionnaires, manage their
history of illness as well as diagnostics, prescriptions
and surgical interventions. The information uploaded
in the platform is not only useful to researchers but also
to individual research participants who can use it, for in-
stance, in their consultations with physicians [27].
The Dynamic Consent platform may be designed to
enable participants to initiate communication with re-
searchers or among themselves, for example via online
discussions, forums and webinars. For instance they may
do so to comment on recruitment and assessment pro-
cesses or to identify new research questions that may be
relevant to them, thus helping researchers to identify fu-
ture research opportunities [58]. The use of the platform
may enhance participants’ understanding of research and
positively impact their willingness to remain in a research
project as their scientific literacy increases, as illustrated by
low withdrawal rates in the Harvard Genome Project [42]
and the CHRIS study (Mascalzoni D, De Grandi A,
Pattaro C, D'Elia J, Pramstaller P, Goegele M, et al.
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Dynamic Consent: building trust through ELSI im-
provements. Six years of Dynamic Consent in the
CHRIS study. Submitted). Participants may also use
the platform to indicate when, how, and by what
means (e.g. telephone, letter, e-mail, SMS, website)
they wish to be notified about new events and in what
circumstances, thus mitigating concerns that they may
feel overwhelmed by continual communication, or
conversely feel insufficiently informed [59].
Consent management
The Dynamic Consent platform allows consent records
to be stored and updated electronically, providing re-
searchers with a reliable and fully tracked overview. Re-
search participants may consult their current and
previous consent decisions at any time. The electronic
storage of consent details enables researchers to confirm
easily the consent status of participants and to audit and
review procedures without the need to refer to individ-
ual paper records. This can significantly reduce the time
taken for audit and improve reliability of the record trail.
The technology to gather and securely store Dynamic
Consent records can be developed so that it is durable
despite rapid software advances and meets security ex-
pectations similar to requirements for electronic health
records [60]. For instance, online consent may be valid
only if provided with an official e-identity or unique user
name and password given by public services [30]. In
principle, the Dynamic Consent platform can also be
linked to other information systems such as Laboratory
Information Management Systems in biobanks [24] and
electronic patient records [33]. These systems can be
automatically updated with the consent preferences of
research participants as these are electronically “tagged”
to each biological sample and/or data [50]. Participants
can enter the platform at any time to review their con-
sents, print a copy, or ask for a copy to be sent by elec-
tronic mail or post [31].
Discussion
The use of Dynamic Consent may facilitate the conduct
of specific research tasks, positively impact recruitment
and retention and simplify the collection and manage-
ment of participants’ consent. It may also potentially
contribute to reducing costs as many activities (such as
sending out information to research participants in the
mail) are conducted online, permit greater operability
across different organisations if built using recognised
national standards [11] and provide researchers with a
practical tool to meet forthcoming legal requirements
for transparency and precise information-giving to par-
ticipants [61]. Importantly, Dynamic Consent may offer
an opportunity for researchers and research participants
to engage in long-term dialogue in a way that goes beyond
the traditional one-off consent process, which may benefit
both parties. Our results are supported by recent recom-
mendations to explore online tools and multimedia inter-
ventions as these have the potential to improve consent
processes and increase participants’ level of comprehen-
sion of the research [62, 63]. Establishing a culture of on-
going communication between researchers and research
participants is increasingly demanded by patient advocacy
groups [64] and research participants [53] who would like
to be consulted about third party access to their data [51,
65] and the management of genetic research results [66].
Increased researcher-research participant communication
is also encouraged by research funders and policymakers
to improve the usefulness and accuracy of research, facili-
tate the development of research projects within areas of
medicine that have been given little priority (such as rare
diseases) and accelerate the translation of research find-
ings to clinical practice [1, 67]. As an illustration, the re-
cently launched Precision Medicine Initiative Cohort
Program [68] which aims to build a national cohort of one
million participants across the United States, recommends
the development of an online platform for “dynamic infor-
mation sharing” that enables participants to “actively en-
gage in an informed, voluntary, and ongoing manner”,
including setting consent preferences or consulting infor-
mation whenever needed, and providing “requested data
when it is convenient for them” [69].
Dynamic Consent platforms are still under develop-
ment and only limited empirical data report experiences
from their use or hurdles to their implementation
[27, 29, 31, 32]. However, several elements need to be
considered by researchers before implementing Dynamic
Consent platforms in their project.
Cost and maintenance
Designing, implementing and maintaining a Dynamic
Consent platform requires staff with good communication
and IT-skills and, in some cases, equipment if potential par-
ticipants cannot use their own device [16]. However, such
costs can reasonably be expected to decrease in the future
as online solutions are likely to become more standardised,
user-friendly and automatic. If researchers are able to use
existing software or are provided with access to a national
platform for Dynamic Consent, as was recently proposed in
Norway [11], this may also reduce investments in IT-
infrastructure [24]. Similarly, links can be provided in the
platform to publicly available tools such as educational vid-
eos, thus limiting the need to produce information material.
Researchers should identify key individuals who may help
them develop a Dynamic Consent platform, investigate col-
laborations with other projects to facilitate platform sharing
or establish whether there is a national platform that could
be used. A budget for the development or use of a platform
should be included in research funding applications.
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Collaboration with research ethics committees
Research ethics committees may not be familiar with
Dynamic Consent solutions, although this is gradually
changing [70]. The implementation of Dynamic Consent
in research projects requires research ethics committees
assessing research projects to adapt from expectations of
participants’ binary yes/no consent status to one that
varies both in scope and across time. Research ethics
committees may need to put greater emphasis on evalu-
ating the functionalities of the tools that are made avail-
able to participants in a research project rather than
scrutinising the type of consent they may give. In the
CHRIS study, the research ethics committee approved
the whole process of Dynamic Consent along with the
informational material. A presentation of the concept
had been provided a few weeks earlier. The committee
agreed that once a participant was informed about the
procedure and gave initial consent in person, he or she
could deal with subsequent consent requests online
(provided security checks and identification means were
in place) [50]. As the use of Dynamic Consent develops,
researchers could collaborate with research ethics com-
mittees to agree upon required criteria for a platform to
qualify as an approved Dynamic Consent platform.
Accessibility of the platform
Some research participants may not have access to the
Internet, may not be the owner of a mobile device, or
may not have the ability to use these technologies [33].
This may be particularly true for the elderly, the disabled
and individuals in socially deprived communities. Recent
experiences from the use of online platforms for consent
show that populations enrolling electronically are less di-
verse in terms of ethnicity and education than popula-
tions enrolled through other means [31]. The positive
effects of using multimedia platforms in the informed
consent process also remain unclear for socio-
economically disadvantaged groups [71]. Furthermore, it
is unknown whether the use of a Dynamic Consent plat-
form fully addresses participants’ needs in terms of hu-
man interaction [32]. Researchers should ensure that
education in the use of online tools is provided to partic-
ipants who request it and that alternative solutions in-
cluding face-to-face meetings are available for those who
cannot use the platform or are not likely to benefit from
its use. Younger people are often experts in the use of
online communication tools; their input to the design of
a Dynamic Consent platform may therefore be useful in
addition to contributions from older people who would
be potential users.
It is inevitable that some research participants will not
want to use the Dynamic Consent platform even if it is
user-friendly and easily accessible. As an illustration,
some patients who are recruited to research through
their clinician may fully trust the clinician’s judgment
and prefer to give a one-off broad consent to participation
in research considering a Dynamic Consent interface un-
necessary. Thus it is important to note that the objective
of using a Dynamic Consent platform is not to force
people to engage in research and communicate with
researchers, but rather to offer them an opportunity to do
so. Results from a recent empirical study aiming to inves-
tigate biobank participants’ experiences of the use of a
Web 2.0 Dynamic Consent interface suggest that once in-
troduced to using an online platform, participants recog-
nise its benefits and find the functions offered by the
platform useful [32]. Disseminating information about the
platform and enabling participants to discuss the platform
together, may indirectly encourage some reluctant partici-
pants to consider its use.
Personal responsibility
Dynamic Consent respects differences between research
participants. Researchers must ensure that this empow-
ering feature of the platform does not lead to undesir-
able side effects [59]. Research participants should not
have to take responsibility for making decisions regard-
ing complex issues that they do not fully grasp or are
not in a position to assess properly [59, 72]. For in-
stance, as data sharing spans several years and a variety
of projects, research participants may struggle to decide
which data sharing scenarios are or are not acceptable to
them. Researchers may use the platform to educate
research participants in the general implications of re-
search including the benefits or risks of data sharing,
using short information videos or frequently asked ques-
tions. Research participants who have a better understand-
ing of what is at stake are more likely to be able to make
informed decisions about data sharing. Finally, participa-
tion in genetic and genomic research may have implica-
tions not only for the individuals recruited to the project
but also for their family. In the future, researchers may
need to take this into consideration when designing com-
munication interfaces for participants [73].
Conclusion
Dynamic Consent, through transparent information ex-
change and ongoing consent, aims to reinforce the infor-
mational, societal and relational value of research and
implies a powerful change in the participant’s role from
passive ‘subject’ to active ‘participant’ [74]. With Dy-
namic Consent, informed consent is not restricted to a
functional or legal instrument, but also becomes a social
agreement between researchers and research participants
[75]. Such change is essential to the creation of new
knowledge, the development of new and adaptive re-
search designs, and the realisation of personalised medi-
cine [1]. It may however generate some anxiety in the
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research community as the active role of participants is
sometimes perceived as potentially threatening [36].
Similar concerns were raised when the Harvard Personal
Genome Project (PGP) implemented an online platform
for Open Consent in 2005 [41]. Open consent means
that participants give their consent to unrestricted dis-
closure of their genotype-phenotype data and are made
fully aware of the risks of participation in the project, in-
cluding loss of confidentiality and privacy through public
disclosure or identification [76]. In the project, ongoing
communication is maintained with participants to collect
knowledge regarding the consequences of participation.
Experiences from the first ten years of the project show
that ongoing communication is perceived as meaningful
both by the research participants and the researchers [42].
When engaging participants in research through a
Dynamic Consent platform, researchers need to be
open-minded, accept that research participants may
raise critical questions and make suggestions, and be
prepared to take these into consideration in the de-
sign of the research. In return, researchers will benefit
from having more engaged, committed and productive
participants in their research; such participants are
useful as demonstrated by the successful contributions
to research made by online communities of patients
[77]. Dynamic Consent could provide a tool that en-
ables researchers to fully benefit from increased inter-
action with participants.
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